Stop using tirzepatide and contact your healthcare provider immediately if you experience severe, persistent abdominal pain with or without vomiting, often radiating to the back
A high proportion of patients achieved significant weight loss, underscoring the drugs potential to improve metabolic outcomes, enhance quality of life, and reduce cardiometabolic risks
The rest really need extra help. AARP Membership Join AARP for only $15 per year with automatic renewal
Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals A pioneering study has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease
You can also read our guide to managing GLP-1 side effects for practical advice
